On July 4, 2017 Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; President: Masayo Tada; "Sumitomo Dainippon Pharma") reported that the Board of Directors of Dainippon Sumitomo Pharma America Holdings, Inc. ("DSPAH"), a holding company in the United States wholly-owned by Sumitomo Dainippon Pharma, decided on July 4, 2017 (US time) that DSPAH will change its name as following (Press release, Dainippon Sumitomo Pharma, JUL 4, 2017, View Source [SID1234519748]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

1. New name
Sumitomo Dainippon Pharma America, Inc.
(Former name: Dainippon Sumitomo Pharma America Holdings, Inc.)

2. Reason for name change
To unify the brand of Sumitomo Dainippon Pharma group by aligning the subsidiary’s name with the parent Company’s name Sumitomo Dainippon Pharma Co., Ltd.

3. Date of the change July 5, 2017 (US time)

4. Outline of DSPAH Company name Dainippon Sumitomo Pharma America Holdings, Inc. Representative Hiroshi Nomura (Chair) Business description Holding company Address of headquarters Wilmington, Delaware, U.S. Capital US1,000$